Table 1.
Patient, disease and transplant characteristics
| Variable | Number (%) |
|---|---|
| Patients | 118 |
| Age at transplant, years | |
| ≤ 5 | 30 (25) |
| 6 – 10 | 38 (32) |
| 11 – 18 | 50 (43) |
| Male | 70 (59) |
| Performance score prior to transplantation | |
| < 90% | 20 (17) |
| 90% – 100% | 91 (77) |
| Not reported | 7 (6) |
| MDS classification (EWOG – MDS) | |
| Refractory cytopenia | 46 (39) |
| Refractory anemia with excess blastsa | 55 (47) |
| Refractory anemia with excess blasts in transformationa | 17 (14) |
| Interval from diagnosis to transplant, months | |
| ≤ 6 | 57 (48) |
| 7 – 12 | 31 (26) |
| > 12 | 30 (26) |
| Cytogenetics | |
| Normal karyotype | 27 (23) |
| Monosomy 7 ± other abnormalities | 39 (33) |
| Complex karyotype (≥ 3 abnormalities) | 18 (15) |
| Other karyotypes | 19 (16) |
| Not reported | 15 (13) |
| Conditioning regimen | |
| Total body irradiation + cyclophosphamide | 80 (68) |
| Total body irradiation + other | 3 (3) |
| Busulfan + cyclophosphamide | 30 (25) |
| Busulfan + other | 4 (3) |
| Melphalan + other | 1 (1) |
| Characteristics of patients | N (%) |
|---|---|
| Graft-versus-host disease prophylaxis | |
| T-cell depletion | 39 (33) |
| Cyclosporine alone | 7 (6) |
| Cyclosporine + methotrexate | 62 (52) |
| Tacrolimus + alone | 1 (1) |
| Tacrolimus + methotrexate | 9 (8) |
| Donor-recipient sex match | |
| Male donor – male recipient | 44 (37) |
| Male donor – female recipient | 17 (14) |
| Female donor – male recipient | 26 (22) |
| Female donor – female recipient | 31 (26) |
| Donor-recipient HLA match | |
| Matched at HLA A, B, C, DRB1 | 36 (31) |
| Mismatched at one or two-loci | 82 (69) |
| Donor-recipient cytomegalovirus serostatus | |
| Donor(−) - recipient(−) | 43 (36) |
| Donor(−) - recipient(+) | 19 (16) |
| Donor(+) - recipient(−) | 30 (26) |
| Donor(+) - recipient(+) | 23 (19) |
| Unknown | 3 (3) |
| Year of transplant | |
| 1990–1994 | 22 (19) |
| 1995–1999 | 63 (53) |
| 2000–2005 | 33 (28) |
| Median (range) follow-up of survivors, months | 92 (3 – 195) |
a
RC at diagnosis and progressed to RAEB prior to transplant: n=6; RAEB at diagnosis and progressed to RAEB-t prior to transplant: n=7